It completely blocks the interaction between PD-1 and PD-L1 expressed on the surface of malignant tumor cells, tumor-infiltrating lymphocytes, antigen-presenting cells, and tumor-infiltrating dendritic cells, which restores the body immune system to monitor and kill tumors[6,7]; At present, tislelizumab has been approved in China for the treatment of classical Hodgkin lymphoma, urothelial carcinoma, non-small cell lung cancer (NSCLC), hepatocellular carcinoma, esophageal squamous cell carcinoma, and gastric/gastroesophageal junction cancer. Here, CD274 is linked to hepatocellular carcinoma.